Blockchain Registration Transaction Record

Helus Pharma Raises $50M to Advance Depression, Anxiety Programs

Helus Pharma announces $50M public offering to fund Phase 3 depression trial (HLP003) and Phase 2 anxiety trial (HLP004). Cantor and Barclays lead the offering. Breakthrough therapy designation in play.

This news matters because Helus Pharma is targeting major depressive disorder and generalized anxiety disorder with novel therapies that could offer durable improvements for millions suffering from these conditions. The $50 million raise accelerates Phase 3 and Phase 2 trials, potentially bringing new treatment options to market faster. Investors and patients should watch for upcoming data readouts that could reshape the mental health landscape.